Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
October 1, 2018
RegMed Investors’ (RMi) pre-open: a new quarter for trading kicks off with a new NAFTA deal called USMCA
September 28, 2018
RegMed Investors’ (RMi) closing bell: the sector navigates the market’s monthly and quarterly close
September 27, 2018
RegMed Investors’ (RMi) pre-open: the numbers are king but, they do bite
September 26, 2018
RegMed Investors’ (RMi) closing bell: kicking the can of equities down with alternating volatility
September 26, 2018
RegMed Investors’ (RMi) pre-open: share pricing is usually collateral damage in this market
September 25, 2018
RegMed Investors’ (RMi) closing bell: the sector is so fickle
September 25, 2018
RegMed Investors’ (RMi) pre-open: sector resilience is based on low volume
September 24, 2018
RegMed Investors’ (RMi) closing bell: it was time for the sector to regenerate
September 24, 2018
RegMed Investors’ (RMi) pre-open: getting closer to Q3’s finish line
September 21, 2018
RegMed Investors’ (RMi) closing bell: another I told you so
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.